Re: Gilead's GS-5829 flops in mCRPC

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Nextblockbuster

Rank: President [?]

Points: 2717 [?]

Votes: 15 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead's GS-5829 flops in mCRPC

in response to

Gilead's GS-5829 flops in mCRPC

BearDownAZ

posted on Jul 13, 2022 12:40PM

Bear, one would think that Gilead with there bad trial results would want to buyout Zenith with the current Phase 1 positive results from the mCRPC trial .

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply